Published in Blood Weekly, March 22nd, 2001
"The Dana-Farber Cancer Institute (DFCI) acute lymphoblastic leukemia (ALL) Consortium Protocol 91-01 was designed to improve the outcome of children with newly diagnosed ALL while minimizing toxicity," explained Lewis B. Silverman and colleagues at that institute.
Five years of follow-up study have confirmed that use of their treatment plan results in a high rate of relapse-free survival, even for high-risk patients, Silverman et al. reported.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.